|3.57||+0.4100||+12.97%||Vol 100.33M||1Y Perf -70.71%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||0.17 4.76%|
|Target Price||29.71||Analyst Rating||Strong Buy 1.33|
|Potential %||732.21||Finscreener Ranking||★★★★ 53.40|
|Insiders Trans % 3/6/12 mo.||-43/-50/-50||Value Ranking||★★★★ 56.13|
|Insiders Value % 3/6/12 mo.||-98/-98/-98||Growth Ranking||★★★+ 54.07|
|Insiders Shares Cnt. % 3/6/12 mo.||-96/-97/-97||Income Ranking||— -|
|Price Range Ratio 52W %||9.81||Earnings Rating||Strong Buy|
|Market Cap||191.81M||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.40|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.61M|
|Avg. Monthly Volume||1.20M|
|Avg. Quarterly Volume||1.18M|
Altimmune Inc. (NASDAQ: ALT) stock closed at 3.57 per share at the end of the most recent trading day (a 12.97% change compared to the prior day closing price) with a volume of 100.33M shares and market capitalization of 191.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Altimmune Inc. CEO is Vipin K. Garg.
The one-year performance of Altimmune Inc. stock is -70.71%, while year-to-date (YTD) performance is -78.3%. ALT stock has a five-year performance of -0.56%. Its 52-week range is between 2.09 and 17.17, which gives ALT stock a 52-week price range ratio of 9.81%
Altimmune Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 3.43, a price-to-sale (PS) ratio of 16 351.20, a price to cashflow ratio of 0.10, a PEG ratio of -, a ROA of -37.62%, a ROC of -42.35% and a ROE of -41.97%. The company’s profit margin is -%, its EBITDA margin is -2 616.80%, and its revenue ttm is $42.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Altimmune Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Altimmune Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Altimmune Inc. is Strong Buy (1.33), with a target price of $29.71, which is +732.21% compared to the current price. The earnings rating for Altimmune Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Altimmune Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Altimmune Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.41, ATR14 : 0.39, CCI20 : 351.72, Chaikin Money Flow : -0.74, MACD : 0.19, Money Flow Index : 97.80, ROC : 46.31, RSI : 77.48, STOCH (14,3) : 35.30, STOCH RSI : 1.00, UO : 34.86, Williams %R : -64.70), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Altimmune Inc. in the last 12-months were: David J. Drutz (Buy at a value of $39 294), Eisenstadt Richard (Buy at a value of $43 100), Eisenstadt Richard (Sold 0 shares of value $0 ), Garg Vipin (Sold 0 shares of value $0 ), GILL JOHN (Sold 2 714 shares of value $40 710 ), M. .Scot Roberts (Sold 0 shares of value $0 ), M. Scot Roberts (Option Excercise at a value of $0), M. Scott Harris (Buy at a value of $42 200), M. Scott Harris (Sold 0 shares of value $0 ), Matthew Scott Harris (Buy at a value of $42 200), Matthew Scott Harris (Option Excercise at a value of $0), Richard I. Eisenstadt (Option Excercise at a value of $0), Vipin K. Garg (Option Excercise at a value of $0), Wayne Pisano (Option Excercise at a value of $52 000), Wayne Pisano (Sold 20 000 shares of value $300 268 )
Wed, 08 Nov 2023 17:00 GMT Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)- TipRanks. All rights reserved.
Wed, 11 Oct 2023 04:15 GMT Altimmunes Obesity Treatment Pemvidutide: A Potential Market Leader with Favorable Risk/Reward Ratio- TipRanks. All rights reserved.
Tue, 12 Sep 2023 15:05 GMT Altimmune (ALT) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Fri, 01 Sep 2023 16:35 GMT Altimmune (ALT) Gets a Buy from B.Riley Financial- TipRanks. All rights reserved.
Mon, 14 Aug 2023 16:01 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT) and Zynerba Pharmaceuticals (ZYNE)- TipRanks. All rights reserved.
Thu, 10 Aug 2023 22:15 GMT Altimmune (ALT) Gets a Buy from JMP Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.